top stories

Af­ter 4 years of furor, the FTC and New York state ac­cuse Mar­tin Shkre­li of run­ning a drug mo­nop­oly. And this time they plan to squash it

6 hours ago
People
Regulatory

UP­DAT­ED: Ac­celeron of­fers thumbs up on a PhII suc­cess for would-be block­buster drug — and shares rock­et up

7 hours ago
R&D

Short at­tack­er Sahm Ad­ran­gi draws crosshairs over a fa­vorite of Sanofi’s new CEO — with PhII da­ta loom­ing

13 hours ago
R&D

Civi­ca and Blue Cross Blue Shield launch new ven­ture to low­er gener­ic prices

12 hours ago
R&D

Latest

Most read

Who knew? Der­mi­ra’s board kept watch as its stock price tracked Eli Lil­ly’s se­cret bid­ding on a $1.1B buy­out

Yesterday
Deals

PPD, Schrödinger, Beam set terms for IPO; FDA ex­pands use of Mer­ck­'s Di­fi­cid

12 hours ago
Protocols

Mer­ck KGaA match­es lofty R&D goals with €250M in­vest­ment in­to a new clin­i­cal man­u­fac­tur­ing site in Switzer­land

12 hours ago
R&D

Breast can­cer ap­proval in tow, As­traZeneca, Dai­ichi armed an­ti­body scores in key gas­tric can­cer study

13 hours ago
Pharma
R&D

Af­ter a brief break, As­traZeneca is back at di­vest­ing — hand­ing off hy­per­ten­sion meds for $350M

13 hours ago
Deals

Sor­ren­to shrugs off an anony­mous pri­vate eq­ui­ty group’s $1B of­fer to buy the com­pa­ny

14 hours ago
R&D
see latest stream
People

Ku­ra co-founder heads to Asian mul­ti-na­tion­al as biotech eyes the goal posts for lead drug

3 days ago

'Y­ou be­trayed that du­ty': For­mer con­gress­man Chris Collins sen­tenced to 26 months in jail for in­sid­er trad­ing

6 days ago

Bernie Sanders goes af­ter Bio­Mar­in's shot at a record drug price, threat­en­ing to break the patent

6 days ago
Startups

Bruce Booth and Saman­tha Truex's lat­est ven­ture aims just above Hu­mi­ra

18 hours ago

Mer­ck KGaA spin­out gets first fund­ing to bring dual-act­ing can­cer mol­e­cules in­to the clin­ic

4 days ago

French-Bel­gian biotech banks €20M to break ground in blood-splat­tered field of ther­a­peu­tic can­cer vac­cines

5 days ago
Deals

UP­DAT­ED: Ab­b­Vie and Al­ler­gan di­vesti­tures are in, and an old As­traZeneca drug comes home

16 hours ago

2019 a 'trans­for­ma­tive year' for phar­ma M&A. Is that a good thing?

3 days ago

Am­gen aug­ments Asia foothold by tak­ing over Astel­las joint ven­ture in Japan

4 days ago
IPOs

Brex­it fears, Wood­ford woes over­shad­owed UK biotech and cut 2019 fi­nanc­ing by al­most half

5 days ago

First Chi­nese biotech on Nas­daq in two years draws $104M

Last week

Shoot­ing for $100M IPO, Schrödinger takes the wraps off its five in­ter­nal drugs and dis­clos­es deal de­tails

2 weeks ago

Premium storiesSee all

#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of ...

Last week
People
R&D

Watch live: End­points at #JPM20

3 weeks ago

Just how big is the bio­phar­ma deal­mak­ing world? In 2019 we saw mega­bil­lions in cash change hands, and that's just the ...

3 weeks ago
Deals

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

4 weeks ago
Pharma
Special

Don't missSee all

A $1B-plus drug stum­bles in­to an­oth­er big PhI­II set­back — this time flunk­ing fu­til­i­ty test — as FDA hold re­mains ...

3 days ago
R&D

Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

3 days ago
R&D

UP­DAT­ED: Eli Lil­ly’s $1.6B can­cer drug failed to spark even the slight­est pos­i­tive gain for pa­tients in its 1st ...

4 days ago
R&D

PureTech bags $200M from sale of Karuna shares — still siz­zling from promis­ing schiz­o­phre­nia da­ta

4 days ago
Deals

Endpoints Standouts

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

4 weeks ago
Pharma
Special

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

2 months ago
People
R&D

Un­lock the full End­points ex­pe­ri­ence for your com­pa­ny — and sup­port our mis­sion of in­de­pen­dent bio­phar­ma re­port­ing

Last month
Publisher's note

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

3 months ago

Peer review See all

Jan
24

Di­a­betes-fo­cused Pox­el names Eli Lil­ly vet David Moller as CSO; Ac­celeron's CBO hops ship to lead start­up

Jan
17

Pe­ter Ciriel­lo takes over the reins at Vy­gon USA; Mirum Phar­ma­ceu­ti­cals taps Ian Clements to the role of CFO

Jan
10

Eli Lil­ly vet jumps aboard Po­laris Part­ners; Mi­rati shakes up its lead­er­ship team with new hires and pro­mo­tions

Jan
3

IQVIA vet takes the helm at Chi­na's Foun­tain Med­ical; Michael Nazak pro­mot­ed to CFO post at Aridis

Dec
20

Bill Lund­berg takes over the reins at Merus; For­mer Akcea COO Jef­frey Gold­berg takes the helm of Im­mu­ni­tas

R&D channel feed

4 days ago

UP­DAT­ED: New play­ers are jump­ing in­to the scram­ble to de­vel­op a vac­cine as pan­dem­ic pan­ic spreads fast

(Ed­i­tor's note: In the last few hours it's been re­port­ed that a new cas­es of the coro­n­avirus have ap­peared in Sin­ga­pore and Sau­di Ara­bia. Chi­nese of­fi­cials say they'll build a spe­cial ...

READ MORE

As­traZeneca makes case for use of blood thin­ner Bril­in­ta in stroke pa­tients

17 hours ago
Pharma

Pas­cal So­ri­ot and As­traZeneca com­mit to ze­ro-car­bon by 2025, car­bon-neu­tral by 2030. Where's the rest of Phar­ma?

4 days ago
latest in R&D

Fresh tri­al da­ta for­ti­fy po­si­tion of Roche's oral ther­a­py in spinal mus­cu­lar at­ro­phy bat­tle­ground

4 days ago

Tran­si­tion­al lead­ers take charge as FDA be­gins PhI­II of OND re­or­ga­ni­za­tion

5 days ago

Io­n­is, Akcea boost­ed by a pos­i­tive PhII for their No­var­tis castoff car­dio drug — and they plan to push ahead in­to piv­otals

5 days ago

What do Mass Gen­er­al, the NCI and Mayo Clin­ic have in com­mon? They rou­tine­ly blow off an FDA rule on post­ing tri­al re­sults

6 days ago

GSK’s ‘break­through’ BC­MA can­cer drug gets a pri­or­i­ty re­view — and a big win for the on­col­o­gy R&D team

6 days ago
see latest stories

Pharma channel feed

3 days ago

Gilead claims Tru­va­da patents in HHS’ com­plaint are in­valid

Back in No­vem­ber, the De­part­ment of Health and Hu­man Ser­vices took the rare step of fil­ing a com­plaint against Gilead for in­fring­ing on gov­ern­ment-owned patents re­lat­ed to the HIV ...

READ MORE

Tri­fec­ta of sick­le cell dis­ease ther­a­pies ex­tend life ex­pectan­cy, but are not cost-ef­fec­tive — ICER

3 days ago

FDA waves Epizyme's $186K rare can­cer drug through to mar­ket — now get ready for the sec­ond act

3 days ago
Regulatory
latest in Pharma

Drug-drug in­ter­ac­tions: FDA is­sues guid­ance on clin­i­cal, in vit­ro stud­ies

3 days ago
Regulatory

Roche cracks Chi­na's ADC mar­ket open as Kad­cy­la scores its first breast can­cer OK in the coun­try

4 days ago
China

Wuhan virus out­break trig­gers in­evitable small-biotech ral­ly

5 days ago

Eli Lil­ly re­serves $470M for new man­u­fac­tur­ing plant — and North Car­oli­na is more than pleased

6 days ago

FDA hands off its lat­est whirl­wind drug OK as Hori­zon hus­tles would-be block­buster to the mar­ket

6 days ago
Regulatory
see latest stories